Advertisement

Journal of Molecular Histology

, Volume 47, Issue 4, pp 429–435 | Cite as

Neuroprotective potential of Linezolid: a quantitative and distribution study via mass spectrometry

  • Sooraj Baijnath
  • Adeola Shobo
  • Linda A. Bester
  • Sanil D. Singh
  • Gert Kruger
  • Per I. Arvidsson
  • Tricia Naicker
  • Thavendran GovenderEmail author
Original Paper

Abstract

A study was undertaken to determine the neuroprotective potential of Linezolid (LIN) in an animal model. Female Sprague–Dawley rats were either given a single (100 mg/kg) dose or treated daily for 4 weeks. A validated LC–MS/MS method was used to measure LIN levels in plasma and brain, this was paired with mass spectrometry imaging to determine the tissue spatial distribution of the drug. The results showed that after a single dose there was poor penetration of the drug into the brain. With multiple doses there were high tissue levels, with the drug reaching steady state in subsequent weeks. LIN displayed a promising distribution pattern with localisation in the brainstem. Systemic circulation is fed into the brain by the carotid and vertebral arteries which enter through the brain stem, therefore high drug concentrations is this area may protect against infectious agents entering via this route.

Keywords

Linezolid Brain MSI LC–MS/MS Neuroprotection Molecular histology 

Supplementary material

10735_2016_9685_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 kb)

References

  1. Ager S, Gould K (2012) Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist 5:87–102PubMedPubMedCentralGoogle Scholar
  2. Baijnath S, Naiker S, Shobo A, Moodley C, Adamson J, Ngcobo B, Bester LA, Singh S, Kruger HG, Naicker T (2015) Evidence for the presence of clofazimine and its distribution in the healthy mouse brain. J Mol Histol 46:439–442CrossRefPubMedGoogle Scholar
  3. Beer R, Engelhardt KW, Pfausler B, Broessner G, Helbok R, Lackner P, Brenneis C, Kaehler ST, Georgopoulos A, Schmutzhard E (2007) Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 51:379–382CrossRefPubMedGoogle Scholar
  4. Chandrasekhar S, Babu G, Mohapatra DK (2011) Practical Syntheses of (2S)-R207910 and (2R)-R207910. Eur J Org Chem 2011:2057–2061CrossRefGoogle Scholar
  5. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V (2014) PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 6:265ra167CrossRefPubMedGoogle Scholar
  6. Dryden MS (2011) Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 66:iv7–iv15PubMedGoogle Scholar
  7. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R (2001) Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45:1843–1846CrossRefPubMedPubMedCentralGoogle Scholar
  8. Krzysztofiak A, Bozzola E, Lancella L, Quondamcarlo A, Gesualdo F, Ugazio AG (2010) Linezolid therapy of brain abscess. Pediatr Infect Dis J 29:1063–1064CrossRefPubMedGoogle Scholar
  9. MacGowan AP (2003) Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51:ii17–ii25CrossRefPubMedGoogle Scholar
  10. Magee DJ (2014) Orthopedic physical assessment. Elsevier Health Sci 3:148–152Google Scholar
  11. Marra A, Lamb L, Medina I, George D, Gibson G, Hardink J, Rugg J, Van Deusen J, O’Donnell JP (2012) Effect of linezolid on the 50 % lethal dose and 50 % protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia. Antimicrob Agents Chemother 56:4671–4675CrossRefPubMedPubMedCentralGoogle Scholar
  12. Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135–142CrossRefPubMedGoogle Scholar
  13. Munyeza CF, Shobo A, Baijnath S, Bratkowska D, Naiker S, Bester LA, Singh SD, Maguire GE, Kruger HG, Naicker T (2015) Rapid and widespread distribution of doxycycline in rat brain: a mass spectrometric imaging study. Xenobiotica 46:385–392CrossRefPubMedGoogle Scholar
  14. Myrianthefs P, Markantonis SL, Vlachos K, Anagnostaki M, Boutzouka E, Panidis D, Baltopoulos G (2006) Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 50:3971–3976CrossRefPubMedPubMedCentralGoogle Scholar
  15. Schecter G, Scott C, True L, Raftery A, Flood J, Mase S (2010) Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 50:49–55CrossRefPubMedGoogle Scholar
  16. Seetharamsingh B, Ramesh R, Dange SS, Khairnar PV, Singhal S, Upadhyay D, Veeraraghavan S, Viswanadha S, Vakkalanka S, Reddy DS (2015) Design, synthesis, and identification of silicon incorporated oxazolidinone antibiotics with improved brain exposure. ACS Med Chem Lett 6:1105–1110CrossRefPubMedGoogle Scholar
  17. Shaikh Z, Peloquin CA, Ericsson CD (2000) Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 33:375–379Google Scholar
  18. Shobo A, Baijnath S, Bratkowska D, Naiker S, Somboro AM, Bester LA, Singh SD, Naicker T, Kruger HG, Govender T (2015a) MALDI MSI and LC-MS/MS: Towards preclinical determination of the neurotoxic potential of fluoroquinolones. Drug Test Anal. doi: 10.1002/dta.1862 PubMedGoogle Scholar
  19. Shobo A, Bratkowska D, Baijnath S, Naiker S, Bester LA, Singh SD, Maguire GEM, Kruger HG, Govender T (2015b) Visualization of time-dependent distribution of rifampicin in rat brain using MALDI MSI and quantitative LCMS/MS. Assay Drug Dev Technol 13:277–284CrossRefPubMedGoogle Scholar
  20. Shobo A, Bratkowska D, Baijnath S, Naiker S, Somboro AM, Bester LA, Singh SD, Naicker T, Kruger HG, Govender T (2015c) Tissue distribution of pretomanid in rat brain via mass spectrometry imaging. Xenobiotica 46:247–252CrossRefPubMedGoogle Scholar
  21. Slatter J, Adams L, Bush E, Chiba K, Daley-Yates P, Feenstra K, Koike S, Ozawa N, Peng G, Sams J (2002) Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907–924CrossRefPubMedGoogle Scholar
  22. Tsona A, Metallidis S, Foroglou N, Selviaridis P, Chrysanthidis T, Lazaraki G, Papaioannou M, Nikolaidis J, Nikolaidis P (2010) Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother 22:17–19CrossRefPubMedGoogle Scholar
  23. Tukaram SA, Smith AA, Muthu AK, Chugh Y, Manavalan R (2007) Systemic safety evaluation of central nervous system function in the rat by oral administration of linezolid. Pharmacol 2: 90–102Google Scholar
  24. Villani P, Regazzi M, Marubbi F, Viale P, Pagani L, Cristini F, Cadeo B, Carosi G, Bergomi R (2002) Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 46:936–937CrossRefPubMedPubMedCentralGoogle Scholar
  25. Youssef S, Hachem R, Chemaly R, Adachi J, Ying J, Rolston K, Raad I (2008) The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother 61:421–424CrossRefPubMedGoogle Scholar
  26. Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, Liu Y (2015) Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 7:603–615PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Sooraj Baijnath
    • 1
  • Adeola Shobo
    • 1
  • Linda A. Bester
    • 2
  • Sanil D. Singh
    • 2
  • Gert Kruger
    • 1
  • Per I. Arvidsson
    • 1
    • 3
  • Tricia Naicker
    • 1
  • Thavendran Govender
    • 1
    Email author
  1. 1.Catalysis and Peptide Research UnitUniversity of KwaZulu-NatalDurbanSouth Africa
  2. 2.Biomedical Resource UnitUniversity of KwaZulu-NatalDurbanSouth Africa
  3. 3.Science for Life Laboratory, Drug Discovery and Development Platform and Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and BiophysicsKarolinska InstitutetStockholmSweden

Personalised recommendations